Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27650628 | 0.81 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL12017706 | 0.81 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL251863 | 0.81 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL19036229 | 0.80 | LMNA (0.58) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL1354709 | 0.79 | LMNA (0.53) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL10915573 | 0.78 | ALDH1A1 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL1237285 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL252117 | 0.78 | CYP3A4 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL12015798 | 0.78 | ALDH1A1 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA | |
| SCHEMBL10232920 | 0.78 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3971176-A1 | AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | Hinova Pharmaceuticals Inc. (CN) | 2022-03-23 | — | — | EP | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2292617-B1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-1888578-B9 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-1888578-B1 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2011-10-13 | — | — | US | disclosed |
| EP-2368889-A1 | Inhibitors of tyrosine kinases | Novartis AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2011-09-08 | — | — | US | disclosed |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | BREITENSTEIN WERNER | 2008-08-07 | — | — | US | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| CN-101045727-A | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-10-03 | — | — | CN | disclosed |
| CN-1324022-C | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2007-07-04 | — | — | CN | disclosed |
| US-20070093506-A1 | Inhibitors of tyrosine kinases | BREITENSTEIN WERNER | 2007-04-26 | — | — | US | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| CN-1675195-A | Tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-09-28 | — | — | CN | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093506-A1 | Inhibitors of tyrosine kinases | ABL1, BTK, FLT3 | CYP1A2 1360/4885CYP3A4 1492/4885CYP2D6 1295/4885 |
| US-20110218187-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | CYP1A2 1360/4885CYP3A4 1492/4885CYP2D6 1295/4885 |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | CYP1A2 1309/4885CYP3A4 1739/4885CYP2D6 2777/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | CYP1A2 4207/4885CYP3A4 4586/4885CYP2D6 4563/4885 |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | CYP1A2 677/4885CYP3A4 1439/4885CYP2D6 1705/4885 |
| US-20080188451-A1 | INHIBITORS OF TYROSINE KINASES | ABL1, BTK, FLT3 | CYP1A2 1360/4885CYP3A4 1492/4885CYP2D6 1295/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | CYP1A2 1531/4885CYP3A4 1455/4885CYP2D6 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.